Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-233 effects on urethral function in healthy females
NCT02113020Phase 1Completed
- Sponsor
- Takeda
- Start
- Feb 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in stress urinary incontinence (SUI) comparing TAK-233 with Placebo (2 arms). Primary endpoint: Change from baseline in motor threshold for urethral sphincter contraction. Started Feb 2014; status: completed.
02
Drugs
TAK-233
03
Conditions
stress urinary incontinence (SUI)
Beyond the preview
Go deeper on NCT02113020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02113020.